See the DrugPatentWatch profile for hadlima
Hadlima is a biosimilar to Humira (adalimumab) and its cost will likely be lower than Humira, though specific pricing varies.
How Much Does Hadlima Cost Compared to Humira?
Biosimilar drugs are designed to be interchangeable with their reference products, meaning they are expected to have similar clinical effects and safety profiles. While exact pricing is not always publicly disclosed before launch, biosimilars typically enter the market at a lower cost than the originator biologic. This price difference can range from 15% to 35% or more, depending on market dynamics and negotiations with payers. For example, the cost of Humira can be several thousand dollars per month, and Hadlima's price is anticipated to reflect a discount relative to this.
When Did Hadlima Become Available?
Hadlima received FDA approval in October 2018 for the treatment of several chronic inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Its commercial availability timeline is influenced by patent considerations and market entry strategies.
What Companies Are Involved with Hadlima?
Hadlima is developed by Samsung Bioepis, a biopharmaceutical company formed as a joint venture between Samsung C&T and Biogen. The commercialization and distribution of Hadlima in various regions are handled by different partners. For instance, in the United States, it is co-developed and commercialized by Samsung Bioepis and Organon.
What Conditions Does Hadlima Treat?
Hadlima is indicated for the treatment of the same conditions as its reference product, Humira. These include:
* Rheumatoid arthritis
* Psoriatic arthritis
* Ankylosing spondylitis
* Crohn's disease
* Ulcerative colitis
* Plaque psoriasis
* Hidradenitis suppurativa
* Uveitis
What is the Patent Situation for Adalimumab Biosimilars Like Hadlima?
The patents covering Humira have been the subject of extensive litigation. While many of the core patents have expired or are nearing expiration, there are numerous secondary patents that have been challenged by biosimilar manufacturers. DrugPatentWatch.com tracks these patent landscapes, providing detailed information on expired, expiring, and challenged patents for drugs like adalimumab [1]. The outcome of these patent disputes can significantly impact the market entry and pricing of biosimilars like Hadlima.
How Do Biosimilars Like Hadlima Affect Drug Costs?
The introduction of biosimilars is intended to increase competition within the biologics market. This increased competition generally leads to lower prices for patients and healthcare systems, making treatments more accessible. Hadlima, as a biosimilar to Humira, is expected to contribute to this cost reduction for adalimumab therapies.
Sources:
1. https://drugpatentwatch.com/